A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
Couriel, Daniel R. [2 ]
Tambaro, Francesco Paolo [1 ]
Gabrail, Nashat [3 ]
Nadeem, Ahmed [4 ]
Kadia, Tapan [1 ]
Jabbour, Elias [1 ]
Borthakur, Gautam [1 ]
Faderl, Stefan [1 ]
Newsome, Willie [1 ]
Yang, Hui [1 ]
Chen, Kevin [5 ]
Stein, Karen [5 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] No Rhode Isl Hematol Oncol Program, Woonsocket, RI USA
[5] Eisai & Co Ltd, Woodcliff Lake, NJ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome
    Montero, Alberto J.
    Estrov, Zeev
    Freireich, Emil J.
    Khouri, Issa F.
    Koller, Charles A.
    Kurzrock, Razelle
    LEUKEMIA & LYMPHOMA, 2006, 47 (10) : 2049 - 2054
  • [22] Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
    Kaiji Zhang
    Ying Lian
    Xiaohong Guan
    Qian Hu
    Lihua Lei
    Li Tao
    Dong He
    Juan Lin
    Zheng Hou
    Lirong Ren
    Xiaoxiao Liu
    Qian Ren
    Lin Pan
    Xiaoli Fei
    Mei Xiong
    Shunzhu Wen
    Jinzhu Cao
    Annals of Hematology, 2020, 99 : 2539 - 2546
  • [23] Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
    Zhang, Kaiji
    Lian, Ying
    Guan, Xiaohong
    Hu, Qian
    Lei, Lihua
    Tao, Li
    He, Dong
    Lin, Juan
    Hou, Zheng
    Ren, Lirong
    Liu, Xiaoxiao
    Ren, Qian
    Pan, Lin
    Fei, Xiaoli
    Xiong, Mei
    Wen, Shunzhu
    Cao, Jinzhu
    ANNALS OF HEMATOLOGY, 2020, 99 (11) : 2539 - 2546
  • [24] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Kantarjian, Hagop M.
    Oki, Yasuhiro
    Issa, Jean-Pierre
    BLOOD, 2006, 108 (13) : 4291 - 4292
  • [25] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Kantarjian, Hagop
    Oki, Yasuhiro
    Garcia-Manero, Guillermo
    Huang, Xuelin
    O'Brien, Susan
    Cortes, Jorge
    Faderl, Stefan
    Bueso-Ramos, Carlos
    Ravandi, Farhad
    Estrov, Zeev
    Ferrajoli, Alessandra
    Wierda, William
    Shan, Jianqin
    Davis, Jan
    Giles, Francis
    Saba, Hussain I.
    Issa, Jean-Pierre J.
    BLOOD, 2007, 109 (01) : 52 - 57
  • [26] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
    Garcia-Manero, Guillermo
    Bachiashvili, Kimo
    Amin, Harshad
    Traer, Elie
    Pollyea, Daniel A.
    Sallman, David A.
    Al-Kali, Aref
    Cripe, Larry D.
    Berdeja, Jesus G.
    Griffiths, Elizabeth A.
    Mohan, Sanjay R.
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold N.
    Yacoub, Abdulraheem
    BLOOD, 2022, 140 : 1112 - 1114
  • [28] Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
    Garcia-Manero, Guillermo
    Bachiashvili, Kimo
    Griffiths, Elizabeth A.
    Zeidan, Amer M.
    Traer, Elie
    Saini, Lalit
    Amin, Harshad
    Mohan, Sanjay
    Lubbert, Michael
    Maness-Harris, Lori
    Foran, James
    Selleslag, Dominik
    Xicoy, Blanca
    Pollyea, Daniel A.
    Sallman, David A.
    Al-Kali, Aref
    Berdeja, Jesus G.
    Al-Ali, Haifa
    Zhu, Nancy Y.
    Lopez, Patricia Font
    Santillana, Guillermo Sanz
    Santini, Valeria
    Yimer, Habte
    Cripe, Larry D.
    Priego, Victor
    Odenike, Olatoyosi
    Heyrman, Bert
    Ferreiras, David Valcarcel
    Vachhni, Pankit J.
    Chan, Winny
    Sano, Yuri
    Mirakhur, Beloo
    Oganesian, Aram
    Keer, Harold
    Yacoub, Abdulraheem
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S376 - S377
  • [29] The Natural History of Lower Risk MDS: Factors Predicting Progression to HighRisk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis E.
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew T.
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2021, 138
  • [30] High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
    Mannone, L
    Gardin, C
    Quarre, MC
    Bernard, JF
    Vassilieff, D
    Ades, L
    Park, S
    Vaultier, S
    Hamza, F
    Beyne-Rauzy, MO
    Cheze, S
    Giraudier, S
    Agape, P
    Legros, L
    Voillat, L
    Dreyfus, F
    Fenaux, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (05) : 513 - 519
12345